home ADDRESS


CATALOG blank PRODUCTS blank ARCHIVES blank FEEDBACK blank SEARCH

DUPLEX STABILIZATION

C-5 propyne derivatives and G-Clamp

Substitution of C-5 propynyl-dC (pdC) for dC and C-5 propynyl-dU (pdU) for dT are effective strategies to enhance base pairing. Using these base substitutions, duplex stability and melting temperatures are raised by the following amounts: C-5 propynyl-C 2.8° per substitution; C-5 propynyl-U 1.7° per substitution. AP-dC (G-clamp) substitutes for dC and is another very important modified nucleoside that enhances hybridization by 7.5° per substitution. The ability of these modified bases to enhance binding while maintaining specificity has proven useful in antisense research and in the synthesis of high affinity probes. AP-dC is also a fluorescent nucleoside and should find uses in DNA structural research.
ItemCatalog No. PackPrice ($)
10-1014-90 100 µmole 85.00
  10-1014-02 0.25g 245.00
  10-1014-05 0.5g 490.00
10-1054-90 100 µmole 65.00
  10-1054-02 0.25g 195.00
  10-1054-05 0.5g 390.00
10-1097-95 50 µmole 230.00
  10-1097-90 100 µmole 460.00
  10-1097-02 0.25g 1175.00

 

INTELLECTUAL PROPERTY

C-5 Propyne Phosphoramidite AND AP-dC-CE Phosphoramidite (G-Clamp)

C-5 Propyne and AP-dC Phosphoramidites
This product is covered by patents or patents pending owned by Isis Pharmaceuticals, Inc. (“Isis”). Purchase of this product includes a limited license to use this product solely for internal research. This license specifically excludes (and you have no right to use this product for): (a) therapeutic or diagnostic applications (including products or services that incorporate this product), (b) any in vivo toxicity/safety study in support of an investigational new drug application (or foreign counterpart), (c) resale (including sale of any products or services that incorporate this product) or (d) gene functionalization activities (including products or services that incorporate data derived from gene functionalization activities) if such activities have commercial application, any and all of which require a separate license from Isis. Neither this product nor any product created through its use may be used in human clinical trials.

A simple agreement must be signed before end-users and custom oligo services may purchase these products for use as defined above.
http://www.glenresearch.com/ Reference/PropyneFax.pdf

OTHER INSTRUMENT TYPES

All minor bases, RNA products and modifiers are packaged in septum-capped vials suitable for ABI and other instruments. If you would like another type of vial/column add the following to the end of the catalog number.

Monomers

For Instrument type
Add
Expedite
E
Beckman Oligo 1000
B
Pharmacia Gene Assembler
P
Mermade
M

Columns

For Instrument type
Add
Applied Biosystems 3900
A
Expedite
E
Mermade
M

Please inquire for availability
of columns for other
instrument types.

bases affecting duplex stability

C-5 methyl pyrimidine nucleosides are known to stabilize duplexes relative to the non-methylated bases. Therefore, enhanced binding can be achieved using 5-methyl-dC in place of dC, duplex melting temperature being increased by 1.3°. Improved stacking in this case is believed to be brought about by elimination of water molecules from the duplex. 2,6-Diaminopurine 2'-deoxyriboside (2-amino-dA) forms an additional hydrogen bond with Thymidine, thereby leading to duplex stabilization with a melting temperature increase of 3°. Our 2-amino-dA monomer exhibits fast and effective deprotection in ammonium hydroxide and it is stabilized to depurination during synthesis. Sequences with high GC content may contain mismatches and still hybridize because of the high stability of the G-C base pair. The N4-ethyl analogue of dC (N4-Et-dC) hybridizes specifically to natural dG but the stability of the base pair is reduced to about the level of an AT base pair.

AP-dC (G-clamp) enhances oligo hybridization since the AP-C....G base pair contains 4 hydrogen bonds, which makes the interaction much stronger than the regular C....G base pair with its 3 hydrogen bonds.

ItemCatalog No. PackPrice ($)
10-1060-90 100 µmole 50.00
  10-1060-02 0.25g 120.00
20-2060-01 0.1g 50.00
1 µmole columns 20-2160-41 Pack of 4 200.00
0.2 µmole columns 20-2160-42 Pack of 4 120.00
10-1085-95 50 µmole 70.00
(2,6-diaminopurine) 10-1085-90 100 µmole 125.00
  10-1085-02 0.25g 250.00
10-1068-95 50 µmole 125.00
  10-1068-90 100 µmole 225.00
  10-1068-02 0.25g 675.00

Locked Nucleic Acid (LNA™) Phosphoramidites

Locked Nucleic Acid (LNA) was first described1 by Wengel and co-workers in 1998 as a novel class of conformationally
restricted oligonucleotide analogues, possessing very high affinity and excellent specificity toward complementary DNA and RNA2. LNA molecules have been used to improve design and efficacy of oligonucleotides directed at regulating gene expression, for example, antisense and siRNA. Incorporating LNA into oligonucleotides has positive effects on delivery to cells, stability, non-specific effects, toxicity, and pharmacokinetics. LNA can also be used to develop more efficient diagnostic tools, for example, probes in genotyping3 and in DNA array design4. Because of their increased affinity, LNA containing probes can be shortened and this is particularly attractive for miRNA expression research5. These properties are detailed in several reviews6.

 

ItemCatalog No. PackPrice ($)
10-2000-90 100 µmole 120.00
  10-2000-02 0.25g 225.00
  10-2000-05 0.5g 450.00
10-2011-90 100 µmole 120.00
  10-2011-02 0.25g 225.00
  10-2011-05 0.5g 450.00
10-2029-90 100 µmole 120.00
  10-2029-02 0.25g 225.00
  10-2029-05 0.5g 450.00
10-2030-90 100 µmole 120.00
  10-2030-02 0.25g 225.00
  10-2030-05 0.5g 450.00

References

(1a) A.A. Koshkin, S.K. Singh, P. Nielsen, V.K. Rajwanshi, R. Kumar, M. Meldgaard, C.E. Olsen, and J. Wengel, Tetrahedron,1998, 54, 3607-3630.
(1b) S.K. Singh, P. Nielsen, A.A. Koshkin, and J. Wengel, Chem. Comm., 1998, (4), 455-456.
(2) L. Kværnø and J. Wengel, Chem. Comm., 1999, (7), 657-658.
(3) L.A. Ugozzoli, D. Latorra, R. Puckett, K. Arar, and K. Hamby, Anal Biochem, 2004, 324, 143-52.
(4) J.P. Liu, et al., Comb Chem High Throughput Screen, 2006, 9, 591-7.
(5) M. Castoldi, et al., RNA, 2006, 12, 913-20.
(6a) D.A. Braasch, D.R. Corey, Biochemistry, 2002, 41, 4503-4510.
(6b) J.S. Jepsen, M.D. Sorensen, and J. Wengel, Oligonucleotides, 2004, 14, 130-146.
(6c) B. Vester, and J. Wengel, Biochemistry, 2004, 43, 13233-41.

INTELLECTUAL PROPERTY

Locked-nucleic Acid (LNA) phosphoramidites are protected by EP Pat No. 1013661, US Pat No. 6,268,490 and foreign applications and patents owned by Exiqon A/S. Products are made and sold under a license from Exiqon A/S. Products are for research purposes only. Products may not be used for diagnostic, clinical, commercial or other use, including use in humans. There is no implied license for commercial use, including contract research, with respect to the products and a license must be obtained directly from Exiqon A/S for such use.

Caps for Increased Duplex Stability and Base-Pairing Fidelity at Termini

New cap structures allow for the preparation of hybridization probes with increased affinity for complementary sequences. The monomers used to prepare capped oligonucleotides are phosphoramidites that can be readily introduced via automated DNA synthesis at the end of solid phase syntheses. The caps favor the formation of stable Watson-Crick duplexes by stacking on the terminal base pair (Figure 1).

FIGURE 1: STACKING OF CAP ON TERMINAL BASE PAIR

Melting point increases of over 10 °C per modification can be realized for short duplexes.1,2 The caps fit canonical Watson-Crick base pairs and do not stack well on mismatched base pairs. This leads to increased base pairing selectivity at the terminal and the penultimate position of oligonucleotides featuring the caps. Base pairing fidelity is usually low at the termini, where fraying occurs frequently in the absence of caps. The beneficial effects of the caps are also realized when longer target strands are bound, so there is no need for blunt ends for the duplexes formed.1,2 The caps, when attached to the terminus of an oligonucleotide, also facilitate purification as their lipophilicity leads to prolonged retention on reversed phase columns or cartridges. Finally, capping of termini may discourage the degradation of oligonucleotides by exonucleases.

ItemCatalog No. PackPrice ($)
10-1986-90 100 µmole 195.00
  10-1986-02 0.25g 495.00
10-1987-90 100 µmole 195.00
  10-1987-02 0.25g 495.00

References

(1) Dogan, Z.; Paulini, R.; Rojas Stütz, J. A.; Narayanan, S.; Richert, C. J. Am. Chem. Soc. 2004, 126, 4762-4763.

(2) Narayanan, S.; Gall, J.; Richert, C. Nucleic Acids Res. 2004, 32, 2901-2911.

 

 

 

http://www.glenres.com/Catalog/duplex.html

 
Please contact Glen Research if you have any questions or comments!
 
Home
About GRC
Catalog
Products
Archives
Search
Site Index